Drozitumab, a Human Antibody to Death Receptor 5, Has Potent Antitumor Activity Against Rhabdomyosarcoma With the Expression of Caspase-8 Predictive of Response

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-10-2874
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy